Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4847253 | 0.96 | MAPK10 (0.51) | MAPK10HSD17B10LMNASMN1; SMN2HPGD | |
| SCHEMBL4847283 | 0.93 | LMNA (0.52) | MAPK10HSD17B10LMNASMN1; SMN2HPGD | |
| SCHEMBL4857054 | 0.89 | ALDH1A1 (0.47) | MAPK10HSD17B10LMNASMN1; SMN2HPGD | |
| SCHEMBL4856563 | 0.89 | MAPK10 (0.47) | MAPK10HSD17B10LMNASMN1; SMN2HPGD | |
| SCHEMBL4855710 | 0.89 | MAPK10 (0.47) | MAPK10HSD17B10LMNASMN1; SMN2HPGD | |
| SCHEMBL4850922 | 0.88 | HTT (0.49) | MAPK10HSD17B10LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL4847260 | 0.88 | KDM4E (0.54) | HSD17B10LMNASMN1; SMN2HPGDNPSR1 | |
| SCHEMBL27631526 | 0.87 | MAPK10 (0.51) | MAPK10HSD17B10LMNASMN1; SMN2HPGD | |
| SCHEMBL4855802 | 0.85 | MAPT (0.47) | MAPK10HSD17B10LMNASMN1; SMN2HPGD | |
| SCHEMBL4847267 | 0.85 | LMNA (0.42) | MAPK10HSD17B10LMNASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361760-B2 | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases | AVANIR PHARMACEUTICALS (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361760-B2 | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases | AVANIR PHARMACEUTICALS (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361760-B2 | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases | AVANIR PHARMACEUTICALS (US) | 2008-04-22 | — | — | US | disclosed |
| US-20070191388-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070191388-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070191388-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2007-08-16 | — | — | US | disclosed |
| CN-1839133-A | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases | AVANIR PHARMACEUTICALS (US) | 2006-09-27 | — | — | CN | disclosed |
| US-20050124604-A1 | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases | AVANIR PHARMACEUTICALS, INC. | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191388-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | MIF, MSR1, SLC11A2 | MAPK10 3983/4885HSD17B10 3906/4885LMNA 673/4885 |
| US-20050124604-A1 | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases | MIF, MSR1, SLC11A2 | MAPK10 3983/4885HSD17B10 3906/4885LMNA 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.